Franklin Resources Inc. Sells 5,730 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Franklin Resources Inc. lowered its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.1% during the third quarter, Holdings Channel.com reports. The firm owned 4,668,130 shares of the medical equipment provider’s stock after selling 5,730 shares during the period. Franklin Resources Inc.’s holdings in Zimmer Biomet were worth $459,811,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Key Financial Inc increased its stake in shares of Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 163 shares in the last quarter. Cullen Frost Bankers Inc. lifted its position in Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 116 shares in the last quarter. Cary Street Partners Investment Advisory LLC grew its holdings in Zimmer Biomet by 83.7% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 149 shares during the last quarter. Root Financial Partners LLC bought a new stake in Zimmer Biomet during the 3rd quarter worth about $31,000. Finally, Mather Group LLC. acquired a new stake in Zimmer Biomet in the 3rd quarter valued at about $36,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 2.3%

Shares of NYSE:ZBH opened at $93.82 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. The stock has a market cap of $18.36 billion, a price-to-earnings ratio of 26.50, a P/E/G ratio of 1.87 and a beta of 0.58. The company has a 50 day moving average of $92.28 and a 200-day moving average of $95.40. Zimmer Biomet Holdings, Inc. has a one year low of $84.59 and a one year high of $114.44.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The business had revenue of $2.24 billion for the quarter, compared to analyst estimates of $2.22 billion. During the same period in the prior year, the business posted $2.31 earnings per share. Zimmer Biomet’s revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio is 27.12%.

Analysts Set New Price Targets

ZBH has been the topic of a number of research reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, January 21st. Sanford C. Bernstein raised their price target on shares of Zimmer Biomet from $97.00 to $99.00 and gave the company a “market perform” rating in a report on Friday, January 9th. Wall Street Zen cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. William Blair began coverage on Zimmer Biomet in a report on Friday, February 20th. They set a “market perform” rating on the stock. Finally, UBS Group reiterated a “sell” rating and issued a $89.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $106.20.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.